This 2026 review explores how cannabinoids might influence autophagy pathways relevant to Alzheimerโs disease. Its value is mainly mechanistic and hypothesis-building, with some discussion of early clinical and preclinical signals. It does not prove that cannabinoids currently offer established disease-modifying treatment for Alzheimerโs disease.
Radical Revelations: The Interplay of Nitrosative Stress, the Endocannabinoid System, and Treatment of Age-Related Disorders.
The crosstalk between the endocannabinoid system (ECS) and reactive nitrogen species (RNS) has emerged as an important area of investigation in recent years….
Neurotransmitter Systems in Alzheimer’s Disease.
Alzheimer’s disease (AD), the leading cause of global dementia, is a multifactorial process that goes beyond the accumulation of ฮฒ-amyloid (Aฮฒ) plaques and t…
Medicinal Cannabis Shows Efficacy for Alzheimer’s Palliative Care – Sechat
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Alzheimer'S DiseasePalliative CareNeuroinflammationBehavioral SymptomsGeriatrics Why This MattersAlzheimer's disease affects nearly 7 million Americans with...
Cannabis-Based Spray Shown Feasible and Safe for Alzheimer’s Agitation in UK Care Homes
Despite significant COVID-19 pandemic-related challenges, administering nabiximols through oral mucosa to advanced Alzheimer’s patients with agitation demonstrated feasibility and safety. These findings support a larger confirmatory efficacy trial.
Three Conference Abstracts Explore Cannabis, Social Isolation, and Dementia Care in Older Adults
Systematic studies of effectiveness and safety in older users of cannabinoids are needed given its increasing use. (NR-7 Conclusions)
Cannabis-Based Spray Shows Early Safety Promise for Alzheimer’s AgitationโBut Proof of Efficacy Still Awaited
Despite significant COVID-19 pandemic-related challenges, administering nabiximols through oral mucosa to advanced Alzheimer’s dementia patients with agitation demonstrated feasibility and safety. These findings support a larger confirmatory efficacy trial.
Assessment of clinical factors that predict response to nabilone for agitation in Alzheimer’s disease: A post hoc analysis of a randomized placebo-controlled trial.
Previously, nabilone showed a medium effect size for treating agitation in moderate-to-severe Alzheimer’s disease (AD), but response varied. These post hoc a…
Inhaled CBD Reduces Key Neuroinflammatory Markers in Alzheimer’s Mouse Model
CBD treatment significantly reduced IDO and cGAS expression, correlating with decreased proinflammatory cytokines, including TNF-ฮฑ, IL-1ฮฒ, and IFN-ฮณ. These findings support CBD as a potential monotherapy or adjunctive treatment for AD by targeting distinct neuroinflammatory pathways.
3 Key Findings: Cannabis Alzheimer’s Treatment Study 2025
Groundbreaking 2025 study shows cannabis Alzheimer’s treatment with low-dose THC-CBD improves cognitive scores in 26-week clinical trial.